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Abstract 
 
Recently we reported widespread intraneuronal PrP immunoreactivity in genetic Creutzfeldt-Jakob 
disease (CJD) associated with the E200K mutation. Here we evaluated six cases of sporadic CJD 
MM type 1, five MV type 2, and seven VV type 2 and compared the anatomical appearance with 29 
E200K genetic CJD cases. In addition, we performed double immunolabeling for ubiquitin, p62, 
early endosomal marker rab5, and immunogold electron microscopy in three cases. Four 
morphological types of intraneuronal PrP immunoreactivity were distinguished: one type defined as 
multiple globular structures was significantly associated with a subset of E200K gCJD cases and 
was distinct from the intraneuronal small dot-like PrP immunoreactivity seen in sporadic CJD. 
While the latter colocalized with rab5, single large (7.5-15 µm) globular inclusion body-like 
structures were detected predominantly but not exclusively in E200K gCJD, immunostained in part 
for ubiquitin and p62, and showed focal γ-tubulin immunoreactivity, suggesting the character of 
aggresomes. Indeed, ultrastructural examination revealed PrP localization in aggresome-like 
structures and in autophagic vacuoles. This suggests that the permanent production of mutant PrP 
overwhelms the ubiquitin-proteasome system and shifts the balance towards selective 
macroautophagy and/or to ubiquitinated inclusion-body and aggresome formation, as a 
cytoprotective effort to sequester the mutant protein. 
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Introduction 
 
Prion diseases belong to the group of neurodegenerative disorders and are characterised by 
deposition of the disease-associated conformer of the cellular prion protein (PrPC), termed PrPSc in 
the brain (1). Neurodegenerative diseases are classified according to the predominant protein that 
accumulates extracellularly as plaques, in synapses, or intracellularly as inclusion bodies (2). The 
protein-based classification of conformational neurodegenerative diseases underpins the importance 
of cellular systems involved in protein housekeeping. PrP, as an aggregate-prone protein, is 
expected to stimulate the clearance mechanisms of the affected cells. The main components of this 
housekeeping protein degradation network are the ubiquitin proteasome system (UPS) and the 
autophagy-lysosome pathway (ALP) (3). In addition, large intracellular protein inclusions called 
aggresomes have been described as key organelles in the segregation and clearance of toxic 
cytoplasmic misfolded proteins (4, 5).  
 
Although our knowledge on the intracellular trafficking and the fate of PrP is incomplete, there are 
already remarkable observations to support the role of these pathways (6, 7). Similarly to amyloid-
beta (Aβ) in Alzheimer`s disease (AD), the processing of PrP and the conversion of PrPC into PrPSc 
most likely involves the endosome-lysosome system (ELS) (8-13). Intraneuronal PrP 
immunoreactivity (IR) has been described in idiopathic or sporadic Creutzfeldt-Jakob disease 
(CJD), in particular associated with type 2 proteinase resistant PrP (14, 15), as well as in different 
animals and experimental models (16-19). These must be distinguished from diffuse neuronal PrP 
immunostaining detected also in non-diseased individuals, most likely representing the cellular 
form of PrP (20). Hovewer, in contrast to tau, alpha-synuclein, TDP-43 (TAR-DNA binding 
protein), and FUS (fused in sarcoma protein), PrPSc has not yet been reported to regularly form 
intracellular inclusions, defined as ubiquitinated aggregates, but deposits preferably in synapses or 
accumulates in the form of plaques extracellularly (1). It must be noted, however, that a study on 
ubiquitin immunostaining in CJD reported that cortical nerve cells contained scanty ubiquitinated 
dot-like inclusions (21), furthermore, inclusion-body like PrP immunopositivity was also reported 
in sporadic CJD (22, 23). The in vitro findings in prion infected cells that the inhibition of 
proteasomes lead to aggresome formation raises the possibility that aggresomes participate in the 
sequestration of PrPSc (24, 25). Nevertheless, aggresomes have not yet been documented in human 
prion disease, thus this potentially cytoprotective mechanism seem to have less relevance for the 
pathogenesis of human disease.  
 
One of the most frequent mutations associated with genetic prion disease of the CJD phenotype is 
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associated with the E200K mutation in the prion protein gene (PRNP). Recently, a systematic study 
on E200K genetic CJD demonstrated intracellular deposition of disease-associated PrP as a frequent 
event (26); there we reported it in approximately 33% of codon 129 MM homozygote cases and in 
71% of MV heterozygotes. We also demonstrated (see supplemental material of Ref. 26) that they 
appear in subcortical regions and brainstem nuclei regularly, and may be prominent in deeper layers 
of the neocortex and CA1 subregion of the hippocampus. In the present study we further 
characterize these intracellular PrP deposits and demonstrate that their distribution and morphology 
distinguishes them from neuron-related PrP IR seen in sporadic CJD cases. Moreover, we find them 
not only in relation to the ELS, but partly forming aggresome-like structures. 
 
Material and methods 
Selection of cases 
We examined six cases of sporadic CJD MM type 1 (3 women, 3 men; mean duration of illness in 
months + standard deviation: 3.3 + 0.5; mean age at death in years: 70 + 2.8), five MV type 2 (3,2; 
19.8 + 16.2; 67.6 + 4.2), and seven VV type 2 (1, 6; 9.2 + 8.4; 69 + 4.8), to evaluate how many 
cases show neuron-related PrP. In these cases we examined the morphological spectrum of 
neuronal-related PrP IR and compared the anatomical predominance with 29 E200K genetic CJD 
(15 MM, 13 MV and 1 VV) cases (26). Post mortem delay varied between 12 and 36 hours. The 
study was performed within a project (“Molecular neuropathologic investigation of 
neurodegenerative diseases”) approved by the Ethical Committee of the Medical University of 
Vienna and is in accordance with the Helsinki Declaration of 1975. 
 
Immunohistochemistry 
For immunohistochemistry 5 mm thick sections of formalin-fixed and paraffin-embedded tissue 
were used with primary antibodies listed here: anti-PrP 12F10 (1:1,000, Cayman Chemical, Ann 
Arbor, MI, USA, epitope: aa. 142-160), anti-PrP BG4 (1:1000, TSE Resource Centre, Birkett CR, 
Compton, U.K.; epitope: aa. 23-85), monoclonal mouse anti-p62 (1:1000, BD Transduction, 
Lexington KY, USA), monoclonal mouse anti-ubiquitin (1:50,000, Millipore, Temecula, CA, 
USA), polyclonal rabbit anti-γ-tubulin (1:500, Santa Cruz. Santa Cruz, CA, USA), polyclonal rabbit 
anti-rab5 (1:500, Calbiochem, San Diego, CA), anti-tau AT8 (pS202, 1:200, Pierce Biotechnology, 
Rockford, IL, USA), anti-phospho-TDP-43 (pS409/410, 1:2,000, Cosmo Bio, Tokyo, Japan), anti-
α-synuclein (1:10,000, clone 4D6, Signet, Dedham, MA, USA), anti-Aβ (1:50, clone 6F/3D, Dako, 
Glostrup, Denmark). The DAKO EnVision© detection kit, peroxidase/DAB, rabbit/mouse (Dako, 
Glostrup, Denmark) was used for visualization of antibody reactions.  
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Evaluation of intraneuronal PrP immunoreactivities (see below) was performed with a dichotomous 
approach (yes/no) in the following anatomical regions: frontal, cingular, parietal, temporal, occipital 
cortex upper and deeper layers; caudate nucleus, putamen, globus pallidus, thalamus medial and 
lateral nuclei; hippocampus CA1 subregion and subiculum; raphe nuclei, pontine base nuclei, 
inferior olives, and dentate nucleus.  
 
Double immunolabeling was performed using monoclonal anti-PrP (12F10), and anti-ubiquitin and 
polyclonal anti-rab5. The fluorescence-labeled secondary antibodies were Alexa Fluor (AF) 555 
donkey anti-mouse IgG (1:200; Molecular Probes, Inc., Eugene, OR, USA), AF 488 goat anti-rabbit 
(1:200; Molecular Probes, Inc.), Zenon AF 488 Mouse IgG1 (Molecular Probes, Inc.). The 
following combinations were applied: PrP/Ubiquitin (including Zenon AF) and PrP/Rab5. Double 
immunolabeling involving anti-PrP antibody was performed after pretreatment of the section with 
20 min heat-induced epitope retrieval with citrate buffer (pH6) followed by 2 min formic acid 
(96%). We evaluated double immunofluorescent labeling with a Zeiss LSM 510 confocal laser 
microscope.  
 
Statistical analysis  
Chi-square statistics was performed to evaluate the proportion of cases showing different types of 
intraneuronal PrP IR and the proportion of involved anatomical regions showing intraneuronal PrP 
IR in those cases, which showed this type of IR. P value below 0.05 was considered significant. 
 
Paraffin-embedded tissue (PET) blotting 
This was performed with slight modifications according to published protocols (27). Briefly, 
sections of formalin fixed, paraffin embedded brain tissue (the same anatomical region as used for 
immunohistochemistry and electron microscopy) was placed onto a nitrocellulose membrane. 
Sections were treated with Proteinase K (Sigma-Aldrich) for eight hours in 56°C. After washing, 
we treated the membranes with 3 M Guanidin Isothiocyanate for 10 minutes. For immunodetection 
we used antibody 3F4 (1:500, monoclonal mouse, Signet).  
 
Immunoelectron microscopy 
After incubation of the deparaffinised tissue sections with anti-PrP (12F10) antibody, we applied 
ultrasmall gold conjugated secondary antibody (Aurion, Wageningen, The Netherlands) followed 
by silver-enhancing method. Slides were mounted with resin and examined in light microscopy. 
Selected areas containing immunoreactive cells were re-embedded for ultrathin sectioning (28). We 
used a JEOL-1011 electron microscope to analyse the ultrastructural localization of PrP-specific 
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immunolabeling in the ultrathin sections. 
 
Results 
 
Morphological spectrum of intraneuronal PrP IR 
We distinguished the following types of neuronal PrP immunopositivities (Fig. 1A): 
Type I: Diffuse cytoplasmic PrP IR without distinct granular or dot-like appearance. We have 
evaluated this type in a previous comprehensive study (20). 
Type II: Many tiny dots in the perikaryon. Sometimes these exhibit a granular appearance of IR. 
The size of the dots ranges between 0.2 and 1.0 µm. 
Type III: Distinct small globular darkly immunostained cytoplasmic PrP immunopositive profiles. 
These are always multiple but their number is less than of type II (usually 5-10), and their size is 
larger, ranging between 1.5 and 4.0 µm. 
Type IV: Distinct single larger globular structures with a size similar to that of the nuclei of the 
neuron, with a range between 7.5 and 15 µm. 
 
In addition, prominent diffuse/synaptic PrP IR is associated with the so called “somato-synaptic” 
pattern defined as tiny dots scattered in or above the microscopic focus-level of the neuronal 
cytoplasm: this was not considered here and was seen in all subtypes of prion disease involved in 
our study. 
 
Distribution of intraneuronal PrP IR  
When pooling all subtypes of sCJD, there was no significant difference between these regarding the 
presence of any type of intraneuronal PrP IR. 
 
Type II neuron-related PrP IR was seen mainly in sCJD VV type 2 and also in MV type 2 cases, but 
not in MM type 1 and less in E200K cases (Fig 1B and Fig 2). When present it appeared in several 
anatomical regions (Fig 1 C): the proportion of involved regions was significantly higher for gCJD 
E200K subtypes when compared to subtypes of sCJD except for more regions in sCJD VV type 2 
when compared to gCJD E200K MM. 
  
Type III was significantly associated with a subset of E200K gCJD cases (MM, MV, VV) in an 
anatomical distribution (Figs. 1B, C and 2) that included predominantly the brainstem, thalamus 
and deeper layers of the cortex (16). Interestingly, where it was available in the examined section, 
we observed this type in the cells of the periventricular germinal matrix (Fig. 2). 
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Type IV was predominantly seen E200K cases, however three sCJD VV type 2 (all in lateral 
thalamus and one in the dentate nucleus as well) and a single MM-1 (dorsal raphe nucleus) also 
showed similar structures (Figs. 1 C and 2). However, in E200K these were always seen in many 
neurons, while in sCJD it was observed in single neurons. In addition, in sCJD brains this was not 
associated with ubiquitin or p62 IR in the same cells.  
 
Light microscopic characterization of intraneuronal PrP IR in E200K gCJD  
PET blot for protease-resistant PrP proved that the intracellular immunopositivities are resistant to 
protease, thus represent disease-associated PrP (Fig. 3 A). Intracellular PrP deposits were not 
detected with an antibody raised against the N-terminal of PrP (Fig. 3 B). Moreover some cells 
contained p62 (Fig. 3 C) but more cells showed ubiquitin-immunopositive structures (Fig. 3 D, E) 
that were immunonegative for α-synuclein, phospho-tau (AT8), phospho-TDP-43, and FUS. In 
addition, occasional neurons with type IV intraneuronal PrP IR exhibited perinuclear γ-tubulin IR 
structures (Fig. 3 F). Double immunolabeling for ubiquitin and disease-associated PrP confirmed 
that these inclusion-body-like structures are partly ubiquitinated (Fig. 3 G), while the smaller dot-
like PrP IR (type II and III) partly co-localized with the early endosomal marker, rab5 (Fig. 3 H). 
 
Ultrastructural observations 
We observed several large PrP-positive intracellular protein inclusions about the size of the nucleus 
in the neurons of the inferior olive (Fig. 4 A, B). Immunogold particles representing disease-
associated PrP accumulated within huge aggresome-like structures in the neighbourhood of the 
nucleus (Fig. 4 A, B). Further PrP-positive granules (Fig. 4 C) were seen in the close vicinity of the 
rough endoplasmic reticulum (RER). The compact appearance of these particles strongly resembled 
pre-aggresomes (Fig. 4 D). Some neurons contained PrP-positive aggregates sequestered in 
spherical, membrane-bound autolysosome-like organelles (Fig. 4 E). Several small vesicles and 
multivesicular bodies also showed PrP-specific immunolabeling (Fig. 4 F, G). 
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Discussion 
 
Here we document neuronal intracytoplasmic inclusion body formation composed of the disease-
associated PrP in genetic CJD associated with the E200K mutation in the PRNP. We could compare 
light microscopy with the ultrastructural immunodetection of the disease-associated PrP in exactly 
the same selected neurons in human tissue (28). In spite of the limitations of post mortem paraffin-
embedded tissue for electron microscopical evaluation, our in vivo results support in vitro studies 
addressing the issue of how the disease-associated (mutant) PrP is processed in the cytoplasm and 
whether it may form intracellular aggregates. 
 
Punctuate intraneuronal PrP immunoreactivity was observed in animals and experimental models of 
prion disease as well as in sporadic CJD, usually associated with certain molecular subtypes (7, 14-
19). In addition, inclusion-body-like structures were reported in five out of eight individuals with 
panencephalopathic type of CJD (without data on the codon 129) in the dentate nucleus (23) and in 
another report in the thalamus (22). Although, intraneuronal ubiquitin immunoreactivity was also 
mentioned in a study (21), here we show that indeed large ubiquitinated inclusions may appear in 
CJD brains. In spite the presence of intraneuronal PrP IR in both sporadic and genetic CJD, our 
present study indicates that a certain morphological type (type III) is distinctive for the E200K 
genetic CJD cases. Interestingly, similar prominent intraneuronal PrP IR was described recently in a 
mouse model of the E200K mutation (29). In addition, the inclusion body-like structures (type IV) 
always involved more neurons in genetic as in sporadic CJD cases. Anatomically, the dentate, the 
inferior olivary nucleus, and pontine base neurons showed mostly these. A comprehensive study of 
intraneuronal PrP in sheep brains, comparing the dorsal motor nucleus of the vagus and the olivary 
nuclei, already suggested that the variability in PrP processing by neurones could be cell-dependent 
(19).    
 
Co-localization of the early-endosomal marker Rab5 and the mutant disease-associated PrP, and the 
presence of PrP in multivesicular bodies support a role for the ELS in the pathogenesis of human 
genetic prion disease. Several studies have shown the involvement of the ELS in experimental 
models of prion disease and also in sporadic CJD (8-11, 30). Indeed, it was recently shown that a 
mild acidic pH is needed for the destabilization of the human codon E200K mutant PrP, 
underpinning the importance of endosomal processing and complementing our morphological 
observations (31, 32). 
 
In addition to the relation to the ELS, we detected disease-associated PrP in close vicinity of RER 
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cisterns as well as large (around the size of the neuronal nucleus) globular PrP-immunopositive 
structures. The relation of mutant PrP to RER cisterns is well in line with the observation that 
untranslocated cytosolic PrP accumulates in the cytosol, is ubiquitinated and serves as a substrate 
for proteasomal degradation (6). Indeed, intracellular inclusion body-like structures showed partial 
ubiquitin and p62 IR. Only extracellular but not intracellular PrP deposits were visualized using an 
antibody against the N-terminal fragment of PrP. On one hand, the frequently noted smaller 
intracytoplasmic immunoreactivities most likely represent truncated PrP, in accordance with its co-
localization with the early endosomal marker rab5. On the other hand, due to their partial ubiquitin 
and p62 immunopositivity, the occasional larger inclusion-like bodies most likely have a cytosolic 
origin, hence their immunonegativity for N-terminal PrP could also suggest conformational 
masking of the N-terminal epitope. 
 
In addition, the morphological appearance and the partial ubiquitin and p62 immunoreactivities of 
the large PrP inclusion bodies suggests the activation of autophagy and/or aggresome formation. 
Recent observations support the notion that ubiquitin attached to the misfolded protein substrates 
can be a common marker for either the UPS or the p62-mediated selective autophagy (33, 34). 
Several data have documented the close relation and coordinated activity of the UPS and 
autophagy. When the cytosolic accumulation of misfolded proteins (i.e. mutant PrP) is permanent 
and the UPS (or the machinery required for substrate sorting to UPS) is consequently overwhelmed, 
autophagy may be induced as a compensatory cytoprotective mechanism (35, 36). Noteworthy, 
significant neuronal autophagy has been reported in scrapie and CJD infected mouse brain as well 
as in human CJD samples (37-40). Moreover, induction of autophagy enhanced the lysosomal 
degradation of endosomally internalised PrPSc in prion-infected cells (41, 42). Nevertheless, further 
studies are needed to elucidate the exact role of the ubiquitin- and p62-dependent selective 
autophagy in the clearance of the cytosolic mutant PrP.  
 
In addition to the above mentioned protein housekeeping systems, aggresome formation has been 
recognized as a secondary defense mechanism. It sequesters and transforms potentially toxic, 
misfolded aggregate-prone proteins into relatively inert inclusions for further degradation (4, 5, 43). 
Thus, until now aggresomes have been reported only in in vitro prion models using proteasome and 
chaperone inhibitors, but never in human prion diseases in vivo. It has been shown that the retro- 
and untranslocated PrP accumulates and forms pre-aggresomes and mature aggresomes in neurons 
(25, 44-46). 
 
It is generally accepted that gCJD with the E200K is not different from sCJD (mainly MM type 1 
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cases) (47). However, there are several differences to be noted: 1) presence of a distinct type of 
intraneuronal PrP IR in all codon 129 variants; 2) presence of a stripe-like pattern of PrP IR in the 
cerebellar cortex that is associated with less prominent spongiform change in the molecular layer 
(26, 48); 3) trend for more prominent involvement of the deeper layers irrespective of codon 129 
constellation (a feature more characteristic of VV type 2 sCJD); 4) lack of amyloid kuru-type 
plaques in cases with MV at codon 129 even when associated with type 2 proteinase resistant PrP 
(as characteristic for sporadic CJD MV type 2); and 5) frequent association with other 
neurodegeneration-related protein deposits. 
 
Our findings in a genetic prion disease (and not in idiopathic forms) argue for the following 
possibilities. First, the dynamics of protein processing may differ between genetic and idiopathic 
CJD. In genetic CJD the protein processing systems are constantly overwhelmed, most likely for a 
longer period, while in idiopathic CJD a more dramatic course can happen with early neuronal 
death and bursting of the disease-associated PrP into the extracellular space. Second, post mortem 
examinations usually reflect a terminal stage, when neurons have been already damaged and some, 
seemingly extracellular, globular protein aggregates may represent formerly intracellular aggregates 
where the neuronal cell body was lysed, analogously to the extracellular Lewy bodies in 
Parkinson`s disease. Indeed, we and others showed ubiquitination of larger extracellular PrP 
deposits in sporadic CJD (21, 49). However, this merits further studies in idiopathic CJD and may 
help to clarify the role of aggresome formation in human prion diseases. From a neuropathological 
diagnostic point of view, presence of ubiquitin or p62 immunoreactive intracellular inclusions that 
are negative for TDP-43, FUS, alpha-synuclein, or phospho-Tau in a neurodegenerative disorder 
might raise the need for additional screening with anti-PrP immunohistochemistry. 
 
In conclusion, our observations support the concept of a complex intracellular pathogenetic scenario 
involving the disease-associated mutant PrP. According to our and other studies, the major players 
are the ELS, the UPS, autophagy, and aggresome formation, which interact in a delicate balance. 
Involvement of this complex system might differ between etiological forms of prion diseases. Since 
not all aspects described here in genetic prion disease have been observed in sporadic (idiopathic) 
forms, patients suffering from genetic vs. idiopathic CJD might require distinct therapeutic 
approaches. 
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Figure legends 
 
Figure 1. Types and distribution of intraneuronal PrP immunoreactivities. 
A: Different types of intraneuronal PrP immunoreactivities. 
B: Distribution of intraneuronal PrP immunoreactivites in sporadic CJD and genetic CJD with 
E200K mutation. 
C: Proportional (%) involvement of examined regions (12 in each case) in cases showing 
intraneuronal PrP immunoreactivity. 
 
Figure 2.  Representative images of intraneuronal immunoreactivities in sporadic (MM type 1: A-
C; VV type 2: D-F; MV type 2:  G-I) and genetic CJD (E200K: MV: J, K, L, N; VV: O; MM: M) in 
the following anatomical regions: Dentate nucleus: F, I; Inferior olive: E, H, L; Hippocampus 
(CA4): D; Thalamus: A, G, K; Pons base: B, N, O; Caudate nucleus: C; Colliculus inferior: J; 
Germinal matrix: M. Scale bar in A represents 10 µm in A-C, E, H, I, M, 20 µm for D, J-L, and 7.5 
µm for M-O. 
 
Figure 3. Light microscopic detection of disease associated PrP. 
A: PET blot for protease-resistant PrP (hippocampus CA1; representative gCJD E00K MV case). B: 
Intracellular PrP deposits are not detected with an antibody raised against the N-terminal of PrP 
(left, frontal cortex; representative gCJD E00K MV case) that otherwise strongly labels 
extracellular PrP (right). Immunostaining for p62 (C, frontal cortex; representative gCJD E00K MV 
case ) and ubiquitin (D, E, frontal cortex: D and E left, inferior olive: E right; representative gCJD 
E00K MV case ) demonstrates intracellular immunopositive structures. F: Immunostaining for PrP 
(left) and γ-tubulin (right, adjacent sections, pontine nuclei neuron from gCJD E200K VV case). 
Double immunolabeling for ubiquitin and disease-associated PrP confirms that these inclusion 
body-like structures are partly ubiquitinated (G,), while the smaller dots-like PrP IR partly co-
localizes with the early endosomal marker, rab5 (H) (both frontal cortex, representative gCJD E00K 
MV case). Scale bar in A represents 10 µm in A, C, E, F, G, H and 25 µm for B and D. 
 
Figure 4. Ultrastructural localization of disease associated PrP. 
A and C: Electron micrographs demonstrate inferior olive neurons containing large PrP-
immunoreactive cytoplasmic inclusions. In the light microscopic insets, the arrows indicate the cells 
that are selected for ultrastructural investigation. A significant accumulation of electron-dense silver 
particles corresponding to disease-associated PrP  (arrowheads) can be observed in an aggresome-
like structure of about the size of the nucleus (B), in the close-vicinity of RER (D) and in spherical 
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autolysosome-like vacuoles (E). Panel G, as a magnified part of panel F, shows a multivesicular 
body containing PrP-specific labeling (arrow) in a lipofuscin (L) rich neuron. Scale bars represent 2 
µm in panel A, C and F, and 0.4 µm in panel B, D and G. 
 
 




